Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults — United States, 2025

Glucagon-like peptide-1 (GLP-1) receptor agonists are medications that help regulate appetite, lower blood glucose levels, and promote weight loss. GLP-1 medications are approved by the Food and Drug Administration (FDA) for type 2 diabetes treatment, chronic weight management, and treatment of certain other health conditions. Data from CDC's Rapid Surveys System were used to examine GLP-1 medication use among U.S. adults. During July-August 2025, approximately one in 10 U.S. adults reported taking a GLP-1 medication during the past year. Among GLP-1 users, approximately one in five reported taking a compounded version. Compounded GLP-1 medications are not reviewed by FDA for safety, effectiveness, or quality before they are marketed. Approximately two in five GLP-1 users modified their use of the medication from the way it was prescribed, often citing cost and availability as barriers to prescribed use. Substantial prevalence of GLP-1 medication use highlights the expanded role of these medications in chronic disease pharmacotherapy. Modifications in medication use, particularly among younger adults, reflect, in part, responses to cost- and access-related challenges. Better understanding of real-world medication use, including dose and frequency adjustments, is important because it might have implications for safety and effectiveness.

Authors

Institutions

Publication Details

Journal
MMWR Morbidity and Mortality Weekly Report
Published
2026-11-12
DOI
https://doi.org/10.15585/mmwr.mm7544a1
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults — United States, 2025

Samantha Lange Pierce, Lilanthi Balasuriya, Alyson B. Goodman, Lyudmyla Kompaniyets
MMWR Morbidity and Mortality Weekly Report
Diabetes Treatment and Management
article

Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults — United States, 2025

Samantha Lange Pierce, Lilanthi Balasuriya, Alyson B. Goodman, Lyudmyla Kompaniyets
article en

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists are medications that help regulate appetite, lower blood glucose levels, and promote weight loss. GLP-1 medications are approved by the Food and Drug Administration (FDA) for type 2 diabetes treatment, chronic weight management, and treatment of certain other health conditions. Data from CDC's Rapid Surveys System were used to examine GLP-1 medication use among U.S. adults. During July-August 2025, approximately one in 10 U.S. adults reported taking a GLP-1 medication during the past year. Among GLP-1 users, approximately one in five reported taking a compounded version. Compounded GLP-1 medications are not reviewed by FDA for safety, effectiveness, or quality before they are marketed. Approximately two in five GLP-1 users modified their use of the medication from the way it was prescribed, often citing cost and availability as barriers to prescribed use. Substantial prevalence of GLP-1 medication use highlights the expanded role of these medications in chronic disease pharmacotherapy. Modifications in medication use, particularly among younger adults, reflect, in part, responses to cost- and access-related challenges. Better understanding of real-world medication use, including dose and frequency adjustments, is important because it might have implications for safety and effectiveness.

MMWR Morbidity and Mortality Weekly ReportVol. 75(44)
Centers for Disease Control and Prevention (US)
Centers for Disease Control and Prevention
Good health and well-being
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon